2024-03-28T22:29:24Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00008010
2022-12-14T03:55:05Z
882:883
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia
Matsuda, K
Nakazawa, Y
Iwashita, C
Kurata, T
Hirabayashi, K
Saito, S
Tanaka, M
Yoshikawa, K
Yanagisawa, R
Sakashita, K
Sasaki, S
Honda, T
Koike, K
PTPN11
SETBP1
JAK3
6-MP
JMML
advance online publication, February 25, 2014
Juvenile myelomonocytic leukemia (JMML) is a fatal, mixed myeloproliferative and myelodysplastic disorder occurring in infancy and early childhood. Children with JMML have mutually exclusive genetic abnormalities in granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathways, inactivation of the NF1 or mutations in PTPN11, NRAS, KRAS and CBL. A whole-exome sequencing study, performed by Sakaguchi et al.,3 has recently demonstrated that in addition to the high frequency of RAS pathway mutations, mutations in SETBP1 and JAK3 are common recurrent secondary events, and that these events may be involved in tumor progression, and are associated with poor clinical outcomes.
Article
LEUKEMIA. 28(7):1545-1548 (2014)
NATURE PUBLISHING GROUP
2014-07
eng
journal article
AM
http://hdl.handle.net/10091/17717
https://soar-ir.repo.nii.ac.jp/records/8010
https://pubmed.ncbi.nlm.nih.gov/24496301
24496301
https://doi.org/10.1038/leu.2014.58
10.1038/leu.2014.58
0887-6924
AA12305962
LEUKEMIA
28
7
1545
1548
https://soar-ir.repo.nii.ac.jp/record/8010/files/Myeloid_progenitors_PTPN11_nonRAS_pathwa_gene.pdf
application/pdf
339.7 kB
2015-09-25